FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.
Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.
Shahrzad A. Zamani discusses the research on cancer disparities in patients within the LGBTQI+ population, and how these findings could inform further research and decisions in clinical practice.